Trials / Not Yet Recruiting
Not Yet RecruitingNCT06745973
An Exploratory Clinical Study Evaluating EPI-003 Injection for the Treatment of Chronic Hepatitis B
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Epigenic Therapeutics, Inc · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, 2-Part (Single Ascending Dose \[Part 1\] And Dose Expansion) study that will evaluate the safety of EPI-003 administered to patients with chronic infection with HBV (CHB). EPI-003 is a liver-targeted antiviral therapeutic for intravenous (IV) injection that is capable of precise epigenetic modifications of the HBV genome without causing mutations in the gene sequence itself.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EPI-003 | Intravenous (IV) infusion. |
Timeline
- Start date
- 2024-12-20
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2024-12-24
- Last updated
- 2024-12-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06745973. Inclusion in this directory is not an endorsement.